Erythromycin Explained

Watchedfields:changed
Verifiedrevid:464189839
Width:200
Tradename:Eryc, Erythrocin, others
Dailymedid:Erythromycin
Pregnancy Au:A
Routes Of Administration:By mouth, intravenous, intramuscular, topical, eye drops
Class:Macrolide antibiotic
Atc Prefix:D10
Atc Suffix:AF02
Legal Au:S4
Legal Uk:POM
Legal Us:Rx-only
Bioavailability:Depends on the ester type; between 30% and 65%
Protein Bound:90%
Metabolism:Liver (under 5% excreted unchanged)
Elimination Half-Life:1.5 hours
Excretion:Bile
Cas Number:114-07-8
Pubchem:12560
Iuphar Ligand:1456
Drugbank:DB00199
Chemspiderid:12041
Unii:63937KV33D
Kegg:D00140
Chebi:42355
Chembl:532
Pdb Ligand:ERY
Iupac Name:(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6--14-ethyl-7,12,13-trihydroxy-4--3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione
C:37
H:67
N:1
O:13
Smiles:CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O
Jmol:none
Stdinchi:1S/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1
Stdinchikey:ULGZDMOVFRHVEP-RWJQBGPGSA-N

Erythromycin is an antibiotic used for the treatment of a number of bacterial infections. This includes respiratory tract infections, skin infections, chlamydia infections, pelvic inflammatory disease, and syphilis. It may also be used during pregnancy to prevent Group B streptococcal infection in the newborn, and to improve delayed stomach emptying.[1] It can be given intravenously and by mouth. An eye ointment is routinely recommended after delivery to prevent eye infections in the newborn.[2]

Common side effects include abdominal cramps, vomiting, and diarrhea. More serious side effects may include Clostridium difficile colitis, liver problems, prolonged QT, and allergic reactions. It is generally safe in those who are allergic to penicillin.[3] Erythromycin also appears to be safe to use during pregnancy.[4] While generally regarded as safe during breastfeeding, its use by the mother during the first two weeks of life may increase the risk of pyloric stenosis in the baby.[5] [6] This risk also applies if taken directly by the baby during this age.[7] It is in the macrolide family of antibiotics and works by decreasing bacterial protein production.[3]

Erythromycin was first isolated in 1952 from the bacteria Saccharopolyspora erythraea.[3] [8] It is on the World Health Organization's List of Essential Medicines.[9] In 2021, it was the 259th most commonly prescribed medication in the United States, with more than 1million prescriptions.[10] [11]

Medical uses

Erythromycin can be used to treat bacteria responsible for causing infections of the skin and upper respiratory tract, including Streptococcus, Staphylococcus, Haemophilus and Corynebacterium genera. The following represents MIC susceptibility data for a few medically significant bacteria:[12]

It may be useful in treating gastroparesis due to this promotility effect. It has been shown to improve feeding intolerances in those who are critically ill.[13] Intravenous erythromycin may also be used in endoscopy to help clear stomach contents to enhance endoscopic visualization, potentially improving diagnostic accuracy and subsequent management.[14]

Available forms

Erythromycin is available in enteric-coated tablets, slow-release capsules, oral suspensions, ophthalmic solutions, ointments, gels, enteric-coated capsules, non enteric-coated tablets, non enteric-coated capsules, and injections.The following erythromycin combinations are available for oral dosage:[15]

For injection, the available combinations are:[15]

For ophthalmic use:

Adverse effects

Gastrointestinal disturbances, such as diarrhea, nausea, abdominal pain, and vomiting, are very common because erythromycin is a motilin agonist.[17]

More serious side effects include arrhythmia with prolonged QT intervals, including torsades de pointes, and reversible deafness. Allergic reactions range from urticaria to anaphylaxis. Cholestasis and Stevens–Johnson syndrome are some other rare side effects that may occur.[18]

Studies have shown evidence both for and against the association of pyloric stenosis and exposure to erythromycin prenatally and postnatally.[19] Exposure to erythromycin (especially long courses at antimicrobial doses, and also through breastfeeding) has been linked to an increased probability of pyloric stenosis in young infants.[20] [21] Erythromycin used for feeding intolerance in young infants has not been associated with hypertrophic pyloric stenosis.[20]

Erythromycin estolate has been associated with reversible hepatotoxicity in pregnant women in the form of elevated serum glutamic-oxaloacetic transaminase and is not recommended during pregnancy. Some evidence suggests similar hepatotoxicity in other populations.[22]

It can also affect the central nervous system, causing psychotic reactions, nightmares, and night sweats.

Interactions

Erythromycin is metabolized by enzymes of the cytochrome P450 system, in particular, by isozymes of the CYP3A superfamily.[23] The activity of the CYP3A enzymes can be induced or inhibited by certain drugs (e.g., dexamethasone), which can cause it to affect the metabolism of many different drugs, including erythromycin. If other CYP3A substrates — drugs that are broken down by CYP3A — such as simvastatin (Zocor), lovastatin (Mevacor), or atorvastatin (Lipitor) — are taken concomitantly with erythromycin, levels of the substrates increase, often causing adverse effects. A noted drug interaction involves erythromycin and simvastatin, resulting in increased simvastatin levels and the potential for rhabdomyolysis. Another group of CYP3A4 substrates are drugs used for migraine such as ergotamine and dihydroergotamine; their adverse effects may be more pronounced if erythromycin is associated.[24]

Earlier case reports on sudden death prompted a study on a large cohort that confirmed a link between erythromycin, ventricular tachycardia, and sudden cardiac death in patients also taking drugs that prolong the metabolism of erythromycin (like verapamil or diltiazem) by interfering with CYP3A4.[25] Hence, erythromycin should not be administered to people using these drugs, or drugs that also prolong the QT interval. Other examples include terfenadine (Seldane, Seldane-D),[26] astemizole (Hismanal),[27] cisapride[28] (Propulsid, withdrawn in many countries for prolonging the QT time) and pimozide (Orap).[29] Interactions with theophylline, which is used mostly in asthma, were also shown.[30]

Erythromycin and doxycycline can have a synergistic effect when combined and kill bacteria (E. coli) with a higher potency than the sum of the two drugs together. This synergistic relationship is only temporary. After approximately 72 hours, the relationship shifts to become antagonistic, whereby a 50/50 combination of the two drugs kills less bacteria than if the two drugs were administered separately.[31]

It may alter the effectiveness of combined oral contraceptive pills because of its effect on the gut flora. A review found that when erythromycin was given with certain oral contraceptives, there was an increase in the maximum serum concentrations and AUC of estradiol and dienogest.[32] [33]

Erythromycin is an inhibitor of the cytochrome P450 system, which means it can have a rapid effect on levels of other drugs metabolised by this system, e.g., warfarin.[34]

Pharmacology

Mechanism of action

Erythromycin displays bacteriostatic activity or inhibits growth of bacteria, especially at higher concentrations.[35] By binding to the 50s subunit of the bacterial rRNA complex, protein synthesis and subsequent structure and function processes critical for life or replication are inhibited.[35] Erythromycin interferes with aminoacyl translocation, preventing the transfer of the tRNA bound at the A site of the rRNA complex to the P site of the rRNA complex.[36] Without this translocation, the A site remains occupied, thus the addition of an incoming tRNA and its attached amino acid to the nascent polypeptide chain is inhibited. This interferes with the production of functionally useful proteins, which is the basis of this antimicrobial action.

Erythromycin increases gut motility by binding to motilin receptor, thus it is a motilin receptor agonist in addition to its antimicrobial properties. It can be therefore administered intravenously as a stomach emptying stimulant.[37]

Pharmacokinetics

Erythromycin is easily inactivated by gastric acid; therefore, all orally administered formulations are given as either enteric-coated or more-stable salts or esters, such as erythromycin ethylsuccinate. Erythromycin is very rapidly absorbed, and diffuses into most tissues and phagocytes. Due to the high concentration in phagocytes, erythromycin is actively transported to the site of infection, where, during active phagocytosis, large concentrations of erythromycin are released.[38]

Metabolism

Most of erythromycin is metabolised by demethylation in the liver by the hepatic enzyme CYP3A4. Its main elimination route is in the bile with little renal excretion, 2%–15% unchanged drug. Erythromycin's elimination half-life ranges between 1.5 and 2.0 hours and is between 5 and 6 hours in patients with end-stage renal disease. Erythromycin levels peak in the serum 4 hours after dosing; ethylsuccinate peaks 0.5–2.5 hours after dosing, but can be delayed if digested with food.[39]

Erythromycin crosses the placenta and enters breast milk. The American Association of Pediatrics determined erythromycin is safe to take while breastfeeding.[40] Absorption in pregnant patients has been shown to be variable, frequently resulting in levels lower than in nonpregnant patients.[41]

Chemistry

Composition

Standard-grade erythromycin is primarily composed of four related compounds known as erythromycins A, B, C, and D. Each of these compounds can be present in varying amounts and can differ by lot. Erythromycin A has been found to have the most antibacterial activity, followed by erythromycin B. Erythromycins C and D are about half as active as erythromycin A.[12] [42] Some of these related compounds have been purified and can be studied and researched individually.

Synthesis

Over the three decades after the discovery of erythromycin A and its activity as an antimicrobial, many attempts were made to synthesize it in the laboratory. The presence of 10 stereogenic carbons and several points of distinct substitution has made the total synthesis of erythromycin A a formidable task.[43] Complete syntheses of erythromycins’ related structures and precursors such as 6-deoxyerythronolide B have been accomplished, giving way to possible syntheses of different erythromycins and other macrolide antimicrobials.[44] Woodward successfully completed the synthesis of erythromycin A, which was published in 1981.[45] [46] [47]

History

In 1949 Abelardo B. Aguilar, a Filipino scientist, sent some soil samples to his employer at Eli Lilly.[48] Aguilar managed to isolate erythromycin from the metabolic products of a strain of Streptomyces erythreus (designation changed to Saccharopolyspora erythraea) found in the samples. Aguilar received no further credit or compensation for his discovery.[49]

The scientist was allegedly promised a trip to the company's manufacturing plant in Indianapolis, but it was never fulfilled. In a letter to the company's president, Aguilar wrote: “A leave of absence is all I ask as I do not wish to sever my connection with a great company which has given me wonderful breaks in life.” The request was not granted.

Aguilar reached out to Eli Lilly again in 1993, requesting royalties from sales of the drug over the years, intending to use them to put up a foundation for poor and sickly Filipinos. This request was also denied. He died in September of the same year.[50]

Lilly filed for patent protection on the compound which was granted in 1953.[51] The product was launched commercially in 1952 under the brand name Ilosone (after the Philippine region of Iloilo where it was originally collected). Erythromycin was formerly also called Ilotycin.

The antibiotic clarithromycin was invented by scientists at the Japanese drug company Taisho Pharmaceutical in the 1970s as a result of their efforts to overcome the acid instability of erythromycin.[52]

Society and culture

Economics

It is available as a generic medication.

In the United States, in 2014, the price increased to seven dollars per tablet.[53]

The price of erythromycin rose three times between 2010 and 2015, from 24 cents per tablet in 2010 to $8.96 in 2015.[54] In 2017, a Kaiser Health News study found that the per-unit cost of dozens of generics doubled or even tripled from 2015 to 2016, increasing spending by the Medicaid program. Due to price increases by drug manufacturers, Medicaid paid on average $2,685,330 more for Erythromycin in 2016 compared to 2015 (not including rebates).[55] By 2018, generic drug prices had climbed another 5% on average.[56]

Brand names

Brand names include Robimycin, E-Mycin, E.E.S. Granules, E.E.S.-200, E.E.S.-400, E.E.S.-400 Filmtab, Erymax, Ery-Tab, Eryc, Ranbaxy, Erypar, EryPed, Eryped 200, Eryped 400, Erythrocin Stearate Filmtab, Erythrocot, E-Base, Erythroped, Ilosone, MY-E, Pediamycin, Zineryt, Abboticin, Abboticin-ES, Erycin, PCE Dispertab, Stiemycine, Acnasol, and Tiloryth.

Veterinary uses

Erythromycin is also used in fishcare for the "broad spectrum treatment and control of bacterial disease". Body slime, mouth fungus, furunculosis, bacterial gill illness, and hemorrhagic septicaemia are all examples of bacterial diseases in fish that may be treated and controlled with this therapy. The usage of Erythromycin in fishcare is mainly limited to therapies targeting gram-positive bacteria.[57]

Notes and References

  1. Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L . Clinical guideline: management of gastroparesis . The American Journal of Gastroenterology . 108 . 1 . 18–37; quiz 38 . January 2013 . 23147521 . 3722580 . 10.1038/ajg.2012.373 .
  2. Matejcek A, Goldman RD . Treatment and prevention of ophthalmia neonatorum . Canadian Family Physician . 59 . 11 . 1187–90 . November 2013 . 24235191 . 3828094 .
  3. Web site: Erythromycin. The American Society of Health-System Pharmacists . 1 August 2015 . live. https://web.archive.org/web/20150906031153/http://www.drugs.com/monograph/erythromycin.html. 6 September 2015.
  4. Web site: Prescribing medicines in pregnancy database. Australian Government . 23 August 2015. live. https://web.archive.org/web/20140408040902/http://www.tga.gov.au/hp/medicines-pregnancy.htm#.U1Yw8Bc3tqw. 8 April 2014.
  5. Book: Hamilton RJ. Tarascon pocket pharmacopoeia. 2013. Jones & Bartlett Learning. [Sudbury, Mass.]. 9781449673611. 72. 2013 delux lab-coat ed., 14th. 9 September 2017. 1 August 2020. https://web.archive.org/web/20200801095144/https://books.google.com/books?id=zJay-fZCFGgC&pg=PA72. live.
  6. Kong YL, Tey HL . Treatment of acne vulgaris during pregnancy and lactation . Drugs . 73 . 8 . 779–87 . June 2013 . 23657872 . 10.1007/s40265-013-0060-0 . 45531743 .
  7. Maheshwai N . Are young infants treated with erythromycin at risk for developing hypertrophic pyloric stenosis? . Archives of Disease in Childhood . 92 . 3 . 271–3 . March 2007 . 17337692 . 2083424 . 10.1136/adc.2006.110007 . https://web.archive.org/web/20121107021907/http://adc.bmj.com/content/92/3/271 . live . 7 November 2012 .
  8. Book: Vedas JC. Biosynthesis : polyketides and vitamins. 2000. Springer. Berlin [u.a.]. 9783540669692. 52. 9 September 2017. 1 August 2020. https://web.archive.org/web/20200801110901/https://books.google.com/books?id=XUuFPxvfWgAC&pg=PA52. live.
  9. Book: ((World Health Organization)) . World Health Organization model list of essential medicines: 22nd list (2021) . 2021 . 10665/345533 . World Health Organization . World Health Organization . Geneva . WHO/MHP/HPS/EML/2021.02 . free .
  10. Web site: The Top 300 of 2021 . ClinCalc . 14 January 2024 . 15 January 2024 . https://web.archive.org/web/20240115223848/https://clincalc.com/DrugStats/Top300Drugs.aspx . live .
  11. Web site: Erythromycin - Drug Usage Statistics . ClinCalc . 14 January 2024.
  12. Web site: Erythromycin Susceptibility and Minimum Inhibitory Concentration (MIC) Data . TOKU-E . 26 February 2014 . 9 May 2015 . https://web.archive.org/web/20150509091111/http://www.toku-e.com/Assets/MIC/Erythromycin.pdf . live .
  13. Lewis K, Alqahtani Z, Mcintyre L, Almenawer S, Alshamsi F, Rhodes A, Evans L, Angus DC, Alhazzani W . The efficacy and safety of prokinetic agents in critically ill patients receiving enteral nutrition: a systematic review and meta-analysis of randomized trials . Critical Care . 20 . 1 . 259 . August 2016 . 27527069 . 4986344 . 10.1186/s13054-016-1441-z . free .
  14. Laine L, Barkun AN, Saltzman JR, Martel M, Leontiadis GI . ACG Clinical Guideline: Upper Gastrointestinal and Ulcer Bleeding . The American Journal of Gastroenterology . 116 . 5 . 899–917 . May 2021 . 33929377 . 10.14309/ajg.0000000000001245 .
  15. Web site: Erythromycin Oral, Parenteral Advanced Patient Information . Drugs.com . live . https://web.archive.org/web/20091130183915/http://www.drugs.com/cons/erythromycin-oral-parenteral.html . 30 November 2009 .
  16. Workowski KA, Berman SM . Sexually transmitted diseases treatment guidelines, 2006 . MMWR: Recommendations and Reports . 55 . RR-11 . 1–94 . August 2006 . 16888612 . https://web.archive.org/web/20100211154655/http://www.cdc.gov/std/treatment/2006/toc.htm . 11 February 2010.
  17. Weber FH, Richards RD, McCallum RW . Erythromycin: a motilin agonist and gastrointestinal prokinetic agent . The American Journal of Gastroenterology . 88 . 4 . 485–90 . April 1993 . 8470625 .
  18. Book: Meyler's Side Effects of Drugs . Elsevier . 2016 . 99–108 . Aronson JK . Erythromycin . Sixteenth . 10.1016/B978-0-444-53717-1.00698-3 . 9780444537164 . https://www.sciencedirect.com/science/article/abs/pii/B9780444537171006983.
  19. Book: Briggs GG, Freeman RK, Yaffe SJ . Drugs in pregnancy and lactation : a reference guide to fetal and neonatal risk . 2011 . Wolters Kluwer Health/Lippincott Williams & Wilkins . Philadelphia . 978-1-60831-708-0 . 9th . Erythromycin . https://books.google.com/books?id=OIgTE4aynrMC&q=erythromycin&pg=PA512 . 20 October 2021 . 23 May 2022 . https://web.archive.org/web/20220523131602/https://books.google.com/books?id=OIgTE4aynrMC&q=erythromycin&pg=PA512 . live .
  20. Maheshwai N . Are young infants treated with erythromycin at risk for developing hypertrophic pyloric stenosis? . Archives of Disease in Childhood . 92 . 3 . 271–3 . March 2007 . 17337692 . 2083424 . 10.1136/adc.2006.110007 .
  21. Lund M, Pasternak B, Davidsen RB, Feenstra B, Krogh C, Diaz LJ, Wohlfahrt J, Melbye M . Use of macrolides in mother and child and risk of infantile hypertrophic pyloric stenosis: nationwide cohort study . BMJ . 348 . g1908 . March 2014 . 24618148 . 3949411 . 10.1136/bmj.g1908 .
  22. McCormack WM, George H, Donner A, Kodgis LF, Alpert S, Lowe EW, Kass EH . Hepatotoxicity of erythromycin estolate during pregnancy . Antimicrobial Agents and Chemotherapy . 12 . 5 . 630–5 . November 1977 . 21610 . 429989 . 10.1128/AAC.12.5.630 .
  23. Hunt CM, Watkins PB, Saenger P, Stave GM, Barlascini N, Watlington CO, Wright JT, Guzelian PS . Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol . Clinical Pharmacology and Therapeutics . 51 . 1 . 18–23 . January 1992 . 1732074 . 10.1038/clpt.1992.3 . 2027.42/109905 . 28056649 . free . 29 August 2019 . 28 August 2021 . https://web.archive.org/web/20210828075533/https://deepblue.lib.umich.edu/bitstream/handle/2027.42/109905/cptclpt19923.pdf;jsessionid=E4EB0A4C0D1D5A07533C041190B23FA0?sequence=1 . live .
  24. Web site: Erythromycine . Belgisch Centrum voor Farmacotherapeutische Informatie . live . https://web.archive.org/web/20151006100756/http://www.bcfi.be/GGR/MPG/MPG_KABA.cfm . 6 October 2015 .
  25. Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM . Oral erythromycin and the risk of sudden death from cardiac causes . The New England Journal of Medicine . 351 . 11 . 1089–96 . September 2004 . 15356306 . 10.1056/NEJMoa040582 . free .
  26. Web site: Drug Interactions between erythromycin and terfenadine . 21 December 2023 . Drugs.com.
  27. Web site: Drug Interactions between astemizole and erythromycin . 21 December 2023 . Drugs.com.
  28. Michalets EL, Williams CR . Drug interactions with cisapride: clinical implications . Clinical Pharmacokinetics . 39 . 1 . 49–75 . July 2000 . 10926350 . 10.2165/00003088-200039010-00004 . 41704853 .
  29. Web site: Erythromycin Interactions . 20 December 2020 . 21 December 2023 . GPnotebook . https://web.archive.org/web/20231221161502/https://gpnotebook.com/pages/ear-nose-and-throat/erythromycin/interactions . 21 December 2023 . live.
  30. Web site: Drug Interactions between erythromycin and theophylline . 21 December 2023 . Drugs.com . https://web.archive.org/web/20231221104101/https://www.drugs.com/drug-interactions/erythromycin-with-theophylline-1009-0-2177-0.html?professional=1 . 21 December 2023 . live.
  31. Pena-Miller R, Laehnemann D, Jansen G, Fuentes-Hernandez A, Rosenstiel P, Schulenburg H, Beardmore R . When the most potent combination of antibiotics selects for the greatest bacterial load: the smile-frown transition . PLOS Biology . 11 . 4 . e1001540 . 23 April 2013 . 23630452 . 3635860 . 10.1371/journal.pbio.1001540 . free .
  32. Blode H, Zeun S, Parke S, Zimmermann T, Rohde B, Mellinger U, Kunz M . Evaluation of the effects of rifampicin, ketoconazole and erythromycin on the steady-state pharmacokinetics of the components of a novel oral contraceptive containing estradiol valerate and dienogest in healthy postmenopausal women . en . Contraception . 86 . 4 . 337–44 . October 2012 . 22445438 . 10.1016/j.contraception.2012.01.010 . 2 August 2019 . 28 August 2021 . https://web.archive.org/web/20210828075535/https://www.contraceptionjournal.org/article/S0010-7824%2812%2900041-8/fulltext . live .
  33. Simmons KB, Haddad LB, Nanda K, Curtis KM . Drug interactions between non-rifamycin antibiotics and hormonal contraception: a systematic review . en . American Journal of Obstetrics and Gynecology . 218 . 1 . 88–97.e14 . January 2018 . 28694152 . 10.1016/j.ajog.2017.07.003 . 36567820 . 2 August 2019 . 28 August 2021 . https://web.archive.org/web/20210828075543/https://www.ajog.org/article/S0002-9378%2817%2930845-1/fulltext . live .
  34. Westphal JF . Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin . British Journal of Clinical Pharmacology . 50 . 4 . 285–295 . October 2000 . 11012550 . 2015000 . 10.1046/j.1365-2125.2000.00261.x .
  35. Book: Section VIII: Chemotherapeutic Drugs; Chapter 44: Chloramphenicol, Tetracyclines, Macrolides, Clindamycin, & Streptogramins . 389–396 . Trevor AJ, Katzung BG, Masters SB . Katzung & Trevor's Pharmacology: Examination & Board Review . 2010 . McGraw-Hill Medical . New York . 978-0-07-170155-6 . 9th.
  36. Web site: Erythromycin . 21 December 2023 . Sigma-Aldrich.
  37. Book: Gastroparesis: Pathophysiology, Clinical Presentation, Diagnosis and Treatment . Parkman HP . Academic Press . 2021 . 323–339 . Chapter 24 - Prokinetic agents for gastroparesis . 10.1016/B978-0-12-818586-5.00024-7 . 9780128185865 . Erythromycin has prokinetic effects because it is a motilin receptor agonist in addition to being an antibiotic. [...] When given intravenously, erythromycin is a potent stimulant of gastric emptying among the available prokinetic drugs. . https://www.sciencedirect.com/science/article/abs/pii/B9780128185865000247.
  38. Lebel M . Pharmacokinetic properties of clarithromycin: A comparison with erythromycin and azithromycin . The Canadian Journal of Infectious Diseases . 4 . 3 . 148–152 . May 1993 . 22346438 . 3250788 . 10.1155/1993/168061 . free .
  39. Book: Edmunds MW, Mayhew MS . Pharmacology for the primary care provider . 2009 . Saint Louis, Missouri . Elsevier Health Sciences . 978-0-323-06316-6 . Third . Chapter 61: Macrolides . 658–662 (661) . https://books.google.com/books?id=9JtgGU0fkggC&pg=PA661 . 3 March 2022 . 23 May 2022 . https://web.archive.org/web/20220523131602/https://books.google.com/books?id=9JtgGU0fkggC&pg=PA661 . live .
    Book: Kirst HA, Sides GD . 1993 . Chapter 28: Erythromycin . Bryskier A, Butzler JP, Neu HC, Tulkens . The Macrolides . Arnette-Blackwell . Oxford UK .
  40. Transfer of drugs and other chemicals into human milk . Pediatrics . 108 . 3 . 776–89 . September 2001 . 11533352 . 10.1542/peds.108.3.776 . American Academy of Pediatrics Committee on Drugs . free .
  41. Philipson A, Sabath LD, Charles D . Erythromycin and clindamycin absorption and elimination in pregnant women . Clinical Pharmacology and Therapeutics . 19 . 1 . 68–77 . January 1976 . 1245094 . 10.1002/cpt197619168 . 7573420 .
  42. Kibwage IO, Hoogmartens J, Roets E, Vanderhaeghe H, Verbist L, Dubost M, Pascal C, Petitjean P, Levol G . Antibacterial activities of erythromycins A, B, C, and D and some of their derivatives . Antimicrobial Agents and Chemotherapy . 28 . 5 . 630–3 . November 1985 . 4091529 . 176346 . 10.1128/aac.28.5.630 .
  43. Pal S . 2006 . A journey across the sequential development of macrolides and ketolides related to erythromycin . Tetrahedron . 62 . 14. 3171–3200 . 10.1016/j.tet.2005.11.064 .
  44. Evans DA, Kim AS . 1997 . Synthesis of 6-Deoxyerythronolide B. Implementation of a General Strategy for the Synthesis of Macrolide Antibiotics . Tetrahedron Lett. . 38 . 53–56 . 10.1016/S0040-4039(96)02258-7 .
  45. Woodward RB, Logusch E, Nambiar KP, Sakan K, Ward DE, Au-Yeung BW, Balaram P, Browne LJ, Card PJ, Chen CH . June 1981 . Asymmetric Total Synthesis of Erythromycin. 1. Synthesis of an Erythronolide A Seco Acid Derivative via Asymmetric Induction . Journal of the American Chemical Society . 103 . 11. 3210–3213 . 10.1021/ja00401a049 .
  46. Woodward RB, Au-Yeung BW, Balaram P, Browne LJ, Ward DE, Au-Yeung BW, Balaram P, Browne LJ, Card PJ, Chen CH . 1981 . Asymmetric Total Synthesis of Erythromycin. 2. Synthesis of an Erythronolide A Lactone System . Journal of the American Chemical Society . 103 . 11. 3213–3215 . 10.1021/ja00401a050 .
  47. Woodward RB, Logusch E, Nambiar KP, Sakan K, Ward DE, Au-Yeung BW, Balaram P, Browne LJ, Card PJ, Chen CH . June 1981 . Asymmetric Total Synthesis of Erythromycin. 3. Total Synthesis of Erythromycin . Journal of the American Chemical Society . 103 . 11. 3215–3217 . 10.1021/ja00401a051 .
  48. News: Tan ML . Drugs and rights . 4 November 2021 . . 30 August 2019 . en . 28 February 2021 . https://web.archive.org/web/20210228125609/https://opinion.inquirer.net/123626/drugs-and-rights . live .
  49. News: Drugs and rights . 30 August 2019 . 21 December 2023 . . Tan ML .
  50. Web site: Hibionada FF . Remembering the battle of Dr. Abelardo Aguilar: Cure for millions, deprived of millions. . The News Today . 22 September 2015 . 18 September 2021 . https://web.archive.org/web/20210918004325/https://www.thenewstoday.info/2005/05/03/iloilonews3.htm . live .
  51. US . 2653899 . Erythromycin, its salts, and method of preparation . Bunch RL, Mcguire JM . Eli Lilly and Company . 29 September 1953 . . .
  52. Book: Greenwood D . Antimicrobial drugs: chronicle of a twentieth century medical triumph . 2008 . Oxford university press . 978-0-19-953484-5 . New York . 239.
  53. Web site: Stahl S . 26 September 2014 . Health: Generic Drugs Prices Increasing . https://web.archive.org/web/20160409212651/http://philadelphia.cbslocal.com/2014/09/26/health-generic-drugs-prices-increasing/ . 9 April 2016 . CBS Philadelphia . 24 March 2016 .
  54. Web site: Terry K . 15 September 2016 . Some Generic Drugs See Huge Price Increases . www.medscape.com . 29 June 2018 . 6 April 2017 . https://web.archive.org/web/20170406005414/http://www.medscape.com/viewarticle/868812 . live .
  55. Web site: Lupkin S . Kaiser Health News . 14 August 2017 . Climbing cost of decades-old drugs threatens to break Medicaid bank . The Philadelphia Inquirer . 29 June 2018 . 29 June 2018 . https://web.archive.org/web/20180629050058/http://www.philly.com/philly/health/health-cents/climbing-cost-of-decades-old-drugs-threatens-to-break-medicaid-bank-20170814.html . live .
  56. News: Marsh T . Are Drugs Really Getting More Expensive? Yes. . The GoodRx Prescription Savings Blog . 29 June 2018 . 27 February 2018 . 23 March 2019 . https://web.archive.org/web/20190323095306/https://www.goodrx.com/blog/are-drugs-getting-more-expensive/ . live .
  57. Web site: CIR 84/FA084: Use of Antibiotics in Ornamental Fish Aquaculture. 14 September 2021. 11 September 2021. https://web.archive.org/web/20210911175940/https://edis.ifas.ufl.edu/publication/FA084. live.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Erythromycin".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.